The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Dilzem     [(4R,5R)-2-(2- dimethylaminoethyl)-5-(4...

Synonyms: Altiazem, Deltazen, Dilatame, Diltelan, Tiazac, ...
This record was replaced with 39186.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of diltiazem


High impact information on diltiazem


Biological context of diltiazem

  • Pharmacokinetics and bioavailability of a sustained-release diltiazem formulation (Mono-Tildiem LP 300 MG) after repeated administration in healthy volunteers [9].
  • A bioequivalence study of three brands of regular diltiazem--Angizem (A), Dilzem (B) and Herbesser (C) has been carried out in 5 healthy, male volunteers [10].
  • Pharmacokinetics showed statistically significant (p < 0.01) differences in AUC0-12 with means (+/- SD) of 519.2(+/- 172.8) and 429.6(+/- 147.2) ng h ml-1, AUC0-36 of 835.6(+/- 281.6) and 730.9 (+/- 271.5) ng h ml-1 and Cmax of 89.1(+/- 30.3) and 61.1(+/- 21.2) ng ml-1 for Cardizem SR and Bi-Tildiem, respectively [11].
  • The AUC (mean +/- S.D.) values in steady state of Cardil and Cardizem were 880.1 +/- 399.8 and 1056.8 +/- 509.8 respectively [12].
  • Over the past thirty years the delivery of health care services in Alaska has gone from Citizen Ban radio transmissions that were relayed through telephone bridges to one of the largest, state of the art telemedicine systems in the world [13].

Anatomical context of diltiazem


Associations of diltiazem with other chemical compounds


Gene context of diltiazem

  • In this paper we describe a generic contact center that was designed in the context of an EU funded IST for health project with acronym Citizen Health System (CHS) [18].
  • ANOVA and multiple comparison tests showed the parent drug AUC0-tau to be significantly higher after daily dosing with Tiazac than with the other 2 marketed products, but the diltiazem Cmin values were not significantly different between the 3 formulations [19].
  • The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study [20].
  • Comparative bioavailability of two formulations of diltiazem (Dilzene, CAS 42399-41-7), a calcium antagonist, was evaluated on 10 healthy volunteers (5 males and 5 females) in a cross-over study [21].

Analytical, diagnostic and therapeutic context of diltiazem

  • The formulations, along with Dilacor XR, were administered to a group eight fasted, healthy volunteers in a four period crossover study [22].
  • METHOD: Students from two schools who had piloted Opportunities for Resuscitation and Citizen Safety (ORCS) in the academic year 2004/2005 volunteered to partake in the study [8].
  • The pH-sensitive microspheres were loaded with diltiazem hydrochloride (DH) [23].
  • The vasodilating effect of CRD-401 on the renal arteries was therefore assumed to be more prominent in a state of renal arterial constriction [14].
  • A comprehensive five-phase evaluation of the first Conference on Citizen CPR was implemented to measure its educational value and impact on attitudes regarding key issues in the lay CPR movement [24].


  1. Anti-ischaemic therapy during the follow-up phase of acute coronary syndromes. Is there a role for calcium channel blockers? Boden, W.E. Drugs (1996) [Pubmed]
  2. A new extended-release formulation of diltiazem HCl for the treatment of mild-to-moderate hypertension. Frishman, W.H. Journal of clinical pharmacology. (1993) [Pubmed]
  3. Effect of morning versus evening dosing of diltiazem on myocardial ischemia detected by ambulatory electrocardiographic monitoring in chronic stable angina pectoris. Dilacor XR Ambulatory Ischemia Study Group. Deedwania, P.C., Pool, P.E., Thadani, U., Eff, J. Am. J. Cardiol. (1997) [Pubmed]
  4. Diltiazem-associated photodistributed hyperpigmentation: a review of 4 cases. Scherschun, L., Lee, M.W., Lim, H.W. Archives of dermatology. (2001) [Pubmed]
  5. Changes in cerebral blood flow accompanied with reduction of blood pressure treatment in patients with hypertensive intracerebral hemorrhages. Kuroda, K., Kuwata, N., Sato, N., Funayama, M., Yabuta, A., Taguchi, S., Suzuki, M., Takahashi, A., Ogawa, A. Neurol. Res. (1997) [Pubmed]
  6. Ca(2+)-channel blockers and nucleoside triphosphate diphosphohydrolase (NTPDase) influence of diltiazem, nifedipine, and verapamil. Gendron, F.P., Latour, J.G., Gravel, D., Wang, Y., Beaudoin, A.R. Biochem. Pharmacol. (2000) [Pubmed]
  7. Effects of benzothiazepine derivative (CRD-401) on blood pressure, excretion of electrolytes, and plasma renin activity. Funyu, T., Nigawara, K., Ohno, K., Hamada, W., Yagihashi, Y. Clinical therapeutics. (1981) [Pubmed]
  8. An evaluation of the effectiveness of the Opportunities for Resuscitation and Citizen Safety (ORCS) defibrillator training programme designed for older school children. Younas, S., Raynes, A., Morton, S., Mackway-Jones, K. Resuscitation. (2006) [Pubmed]
  9. Pharmacokinetics and bioavailability of a sustained-release diltiazem formulation (Mono-Tildiem LP 300 MG) after repeated administration in healthy volunteers. Bianchetti, G., Dubruc, C., Sultana, V., Houin, G., Rosenzweig, P. Eur. J. Clin. Pharmacol. (1995) [Pubmed]
  10. Bioinequivalence of marketed diltiazem preparations. Joshi, M.V., Gokhale, P.C., Pohujani, S.M., Dalvi, S.S., Karandikar, S.M., Kshirsagar, N.A. Eur. J. Clin. Pharmacol. (1990) [Pubmed]
  11. Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers. Guimont, S., Landriault, H., Klischer, K., Grace, M., Lambert, C., Caillé, G., Gossard, D., Russell, A., Raymond, M., Hutchings, E. Biopharmaceutics & drug disposition. (1993) [Pubmed]
  12. Single-dose and steady-state pharmacokinetics of diltiazem administered in two different tablet formulations. Christrup, L.L., Bonde, J., Rasmussen, S.N., Sonnergaard, J.M., Jensen, B.H. Pharmacol. Toxicol. (1992) [Pubmed]
  13. Arctic telehealth: north to the future. Hild, C. International journal of circumpolar health. (2004) [Pubmed]
  14. Effects of diltiazem Hydrochloride (CRD-401) on renal hemodynamics of dogs. Ishikawa, H., Matsushima, M., Matsui, H., Honjo, A., Hayashi, M., Shindo, T., Morifuji, T., Okaybayashi, M. Arzneimittel-Forschung. (1978) [Pubmed]
  15. Effects of diltiazem hydrochloride (CRD-401) on hepatic, superior mesenteric and femoral hemodynamics. Ishikawa, H., Matsushima, A., Matsui, H., Shindo, T., Morifuji, T., Okabayashi, M. Arzneimittel-Forschung. (1978) [Pubmed]
  16. A pitfall of the diagnostic process of differentiating bile peritonitis from acute appendicitis. Moriwaki, Y., Sugiyama, M., Mochizuki, Y., Yamazaki, Y., Suda, T., Hasegawa, S., Matsuda, G., Karube, N., Uchida, K., Yamamoto, T. Hepatogastroenterology (2004) [Pubmed]
  17. Steady-state pharmacokinetics of high-dose diltiazem hydrochloride (Cardizem CD) administered once daily in healthy volunteers. Robbins-Weilert, D.K., Giesing, D.H., Weir, S.J. American journal of therapeutics. (1999) [Pubmed]
  18. Home care delivery through the mobile telecommunications platform: the Citizen Health System (CHS) perspective. Maglaveras, N., Koutkias, V., Chouvarda, I., Goulis, D.G., Avramides, A., Adamidis, D., Louridas, G., Balas, E.A. International journal of medical informatics. (2002) [Pubmed]
  19. Comparison of diltiazem bioavailability from 3 marketed extended-release products for once-daily administration: implications of chronopharmacokinetics and dynamics. Eradiri, O., Midha, K.K. International journal of clinical pharmacology and therapeutics. (1997) [Pubmed]
  20. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. Muhlestein, J.B., May, H.T., Jensen, J.R., Horne, B.D., Lanman, R.B., Lavasani, F., Wolfert, R.L., Pearson, R.R., Yannicelli, H.D., Anderson, J.L. J. Am. Coll. Cardiol. (2006) [Pubmed]
  21. Comparative bioavailability of two tablet preparations of diltiazem in healthy volunteers. De Bernardis, E., Candido, P., Lorefice, R., Picari, M., Rizza, V. Arzneimittel-Forschung. (1992) [Pubmed]
  22. Guar gum-based sustained release diltiazem. Altaf, S.A., Yu, K., Parasrampuria, J., Friend, D.R. Pharm. Res. (1998) [Pubmed]
  23. Preparation of Novel Cationic Copolymer Microspheres and Evaluation of Their Function by In Vitro and In Vivo tests as Ph-Sensitive Drug Carrier Systems. Sun, C., Liu, H., Zhang, S., Li, X., Pan, W. Drug development and industrial pharmacy. (2006) [Pubmed]
  24. Evaluating the impact of a conference. Gombeski, W.R., Farge, E.J., Ramirez, A.G., Moore, T.J., Freyer, B.S., Weaver, F.J. Health matrix. (1984) [Pubmed]
WikiGenes - Universities